Menu Search
Equities

T2 Biosystems Inc

3T2:FRA

T2 Biosystems Inc

Actions
  • Price (EUR)0.548
  • Today's Change0.00 / 0.00%
  • Shares traded620.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 07:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year T2 Biosystems Inc had revenues fall -67.75% from 22.31m to 7.19m, though the company grew net income from a loss of 62.00m to a smaller loss of 50.08m.
Gross margin-86.96%
Net profit margin-673.67%
Operating margin-629.55%
Return on assets-164.01%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, T2 Biosystems Inc increased its cash reserves by 36.70%, or 4.36m. Cash Flow from Financing totalled 52.69m or 732.49% of revenues. In addition the company used 48.14m for operations while cash used for investing totalled 192.00k.
Cash flow per share-7.27
Price/Cash flow per share--
Book value per share-0.3391
Tangible book value per share-0.3391
More ▼

Balance sheet in USDView more

T2 Biosystems Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.5962
Quick ratio0.359
Total debt/total equity--
Total debt/total capital2.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.